In the Sept. 20, 2023, Customs Bulletin and Decisions, U.S. Customs and Border Protection proposed to reclassify sildenafil citrate in bulk form as a sulfonamide under HTSUS 2935.90.60 (duty-free under the Pharmaceutical Appendix) rather than as a heterocyclic compound with nitrogen heteroatoms only under HTSUS 2933.59.5300 (duty-free under the Pharmaceutical Appendix).
The product at issue is a drug that produces the dilatation of blood vessels and is used to treat erectile dysfunction and high blood pressure in the lungs.
Rulings NY H83763 and NY B87488 would be revoked to reflect the proposed reclassification. Comments on this proposal are due no later than Oct. 20.
For more information on how to seek or utilize classification and other rulings, please contact attorney Deb Stern at (305) 894-1007 or via email.
Click here for more information on ST&R’s upcoming webinars on classification issues.
Copyright © 2025 Sandler, Travis & Rosenberg, P.A.; WorldTrade Interactive, Inc. All rights reserved.